For US Residents Only

Understanding Metastatic Castration-Resistant Prostate Cancer

PLUVICTO is used for the treatment of PSMA-positive metastatic castration-resistant prostate cancer

Prescribing Information

Patient Support Line

1-844-638-7222

Mon-Fri: 8 AM-8 PM ET

Patient Support Line

1-844-638-7222

Mon-Fri: 8 AM-8 PM ET

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased ris...

What is PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:

has spread to other parts of the body (metastatic), and
has...

< Back To Site

Metastatic prostate cancer is a type of prostate cancer that has spread to other parts of your body.

Metastatic castration-resistant prostate cancer (mCRPC) is a type of prostate cancer that has spread to other parts of your body and is no longer responding to hormone treatment that lowers testosterone
PSMA (prostate-specific membrane antigen) is a biomarker that sits on the outside of prostate cancer cells and is detected by a PSMA positron emission tomography (PET) scan

If your prostate cancer cells have an abundance of PSMA, it means your mCRPC is PSMA positive (PSMA+). PSMA+ cancer cells can be targeted with PLUVICTO^™ (lutetium Lu 177 vipivotide tetraxetan).

Noncancerous PSMA+ cells and other surrounding cells will also will be impacted.

PSMA is an important biomarker and is found in more than 80% of patients with prostate cancer.

You can find out if your prostate cancer is PSMA+ by having a PSMA PET scan

A PSMA PET scan is an imaging test that allows your doctor to check for PSMA+ cancer in your body

Ask your doctor about treating your metastatic prostate cancer with PLUVICTO.

Next: How Pluvicto Works >